A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity

Abroad (travel likely)RecruitingPHASE1

Conditions

Refractory Malignant Solid Tumors · mRNA Vaccine · Interleukin

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

West China Hospital of Sichuan University, Chengdu, Sichuan, China
Contact: Study coordinator (Xingchen Peng, PhD) · 18980606753

Study leads

Xingchen Peng
Principal Investigator
West China Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.

Refractory Malignant Solid Tumors · mRNA Vaccine · Interleukin

Abroad (travel likely)RecruitingPHASE1

Chengdu, China · Chengdu, China

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Malignant Solid Tumors · Other Neoplasms Solid Tumors · Pediatric Solid Tumor

Abroad (travel likely)Recruiting

Bethesda, United States · Portland, United States

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Refractory Solid Tumor · Hepatocellular Carcinoma · Malignant Solid Tumor

Abroad (travel likely)RecruitingPHASE1, PHASE2

Germantown, United States · Memphis, United States

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Wilms Tumor · Rhabdoid Tumor · Malignant Peripheral Nerve Sheath Tumors

Abroad (travel likely)RecruitingPHASE2

Los Angeles, United States · Palo Alto, United States